Momordica charantia, a Nutraceutical Approach for Inflammatory Related Diseases
, commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and nutritional properties. Due to the presence of many bioactive compounds, some of which possess potent biological actions, this plant is used in folk medicine all o...
Saved in:
| Published in | Frontiers in pharmacology Vol. 10; p. 486 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
08.05.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | , commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and nutritional properties. Due to the presence of many bioactive compounds, some of which possess potent biological actions, this plant is used in folk medicine all over the world for the treatment of different pathologies, mainly diabetes, but also cancer, and other inflammation-associated diseases. It is widely demonstrated that
extracts contribute in lowering glycaemia in patients affected by type 2 diabetes. However, the majority of existing studies on
bioactive compounds were performed only on cell lines and in animal models. Therefore, because the real impact of bitter melon on human health has not been thoroughly demonstrated, systematic clinical studies are needed to establish its efficacy and safety in patients. Besides, both
and
studies have demonstrated that bitter melon may also elicit toxic or adverse effects under different conditions. The aim of this review is to provide an overview of anti-inflammatory and anti-neoplastic properties of bitter melon, discussing its pharmacological activity as well as the potential adverse effects. Even if a lot of literature is available about bitter melon as antidiabetic drug, few papers discuss the anti-inflammatory and anti-cancer properties of this plant. |
|---|---|
| AbstractList | Momordica charantia, commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and nutritional properties. Due to the presence of many bioactive compounds, some of which possess potent biological actions, this plant is used in folk medicine all over the world for the treatment of different pathologies, mainly diabetes, but also cancer, and other inflammation-associated diseases. It is widely demonstrated that M. charantia extracts contribute in lowering glycaemia in patients affected by type 2 diabetes. However, the majority of existing studies on M. charantia bioactive compounds were performed only on cell lines and in animal models. Therefore, because the real impact of bitter melon on human health has not been thoroughly demonstrated, systematic clinical studies are needed to establish its efficacy and safety in patients. Besides, both in vitro and in vivo studies have demonstrated that bitter melon may also elicit toxic or adverse effects under different conditions. The aim of this review is to provide an overview of anti-inflammatory and anti-neoplastic properties of bitter melon, discussing its pharmacological activity as well as the potential adverse effects. Even if a lot of literature is available about bitter melon as antidiabetic drug, few papers discuss the anti-inflammatory and anti-cancer properties of this plant. Momordica charantia, commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and nutritional properties. Due to the presence of many bioactive compounds, some of which possess potent biological actions, this plant is used in folk medicine all over the world for the treatment of different pathologies, mainly diabetes, but also cancer, and other inflammation-associated diseases. It is widely demonstrated that M. charantia extracts contribute in lowering glycaemia in patients affected by type 2 diabetes. However, the majority of existing studies on M. charantia bioactive compounds were performed only on cell lines and in animal models. Therefore, because the real impact of bitter melon on human health has not been thoroughly demonstrated, systematic clinical studies are needed to establish its efficacy and safety in patients. Besides, both in vitro and in vivo studies have demonstrated that bitter melon may also elicit toxic or adverse effects under different conditions. The aim of this review is to provide an overview of anti-inflammatory and anti-neoplastic properties of bitter melon, discussing its pharmacological activity as well as the potential adverse effects. Even if a lot of literature is available about bitter melon as antidiabetic drug, few papers discuss the anti-inflammatory and anti-cancer properties of this plant.Momordica charantia, commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and nutritional properties. Due to the presence of many bioactive compounds, some of which possess potent biological actions, this plant is used in folk medicine all over the world for the treatment of different pathologies, mainly diabetes, but also cancer, and other inflammation-associated diseases. It is widely demonstrated that M. charantia extracts contribute in lowering glycaemia in patients affected by type 2 diabetes. However, the majority of existing studies on M. charantia bioactive compounds were performed only on cell lines and in animal models. Therefore, because the real impact of bitter melon on human health has not been thoroughly demonstrated, systematic clinical studies are needed to establish its efficacy and safety in patients. Besides, both in vitro and in vivo studies have demonstrated that bitter melon may also elicit toxic or adverse effects under different conditions. The aim of this review is to provide an overview of anti-inflammatory and anti-neoplastic properties of bitter melon, discussing its pharmacological activity as well as the potential adverse effects. Even if a lot of literature is available about bitter melon as antidiabetic drug, few papers discuss the anti-inflammatory and anti-cancer properties of this plant. , commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and nutritional properties. Due to the presence of many bioactive compounds, some of which possess potent biological actions, this plant is used in folk medicine all over the world for the treatment of different pathologies, mainly diabetes, but also cancer, and other inflammation-associated diseases. It is widely demonstrated that extracts contribute in lowering glycaemia in patients affected by type 2 diabetes. However, the majority of existing studies on bioactive compounds were performed only on cell lines and in animal models. Therefore, because the real impact of bitter melon on human health has not been thoroughly demonstrated, systematic clinical studies are needed to establish its efficacy and safety in patients. Besides, both and studies have demonstrated that bitter melon may also elicit toxic or adverse effects under different conditions. The aim of this review is to provide an overview of anti-inflammatory and anti-neoplastic properties of bitter melon, discussing its pharmacological activity as well as the potential adverse effects. Even if a lot of literature is available about bitter melon as antidiabetic drug, few papers discuss the anti-inflammatory and anti-cancer properties of this plant. Momordica charantia , commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and nutritional properties. Due to the presence of many bioactive compounds, some of which possess potent biological actions, this plant is used in folk medicine all over the world for the treatment of different pathologies, mainly diabetes, but also cancer, and other inflammation-associated diseases. It is widely demonstrated that M. charantia extracts contribute in lowering glycaemia in patients affected by type 2 diabetes. However, the majority of existing studies on M. charantia bioactive compounds were performed only on cell lines and in animal models. Therefore, because the real impact of bitter melon on human health has not been thoroughly demonstrated, systematic clinical studies are needed to establish its efficacy and safety in patients. Besides, both in vitro and in vivo studies have demonstrated that bitter melon may also elicit toxic or adverse effects under different conditions. The aim of this review is to provide an overview of anti-inflammatory and anti-neoplastic properties of bitter melon, discussing its pharmacological activity as well as the potential adverse effects. Even if a lot of literature is available about bitter melon as antidiabetic drug, few papers discuss the anti-inflammatory and anti-cancer properties of this plant. |
| Author | Polito, Letizia Bortolotti, Massimo Mercatelli, Daniele |
| AuthorAffiliation | 2 Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna , Bologna , Italy 1 Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna , Bologna , Italy |
| AuthorAffiliation_xml | – name: 1 Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna , Bologna , Italy – name: 2 Department of Pharmacy and Biotechnology, Alma Mater Studiorum, University of Bologna , Bologna , Italy |
| Author_xml | – sequence: 1 givenname: Massimo surname: Bortolotti fullname: Bortolotti, Massimo – sequence: 2 givenname: Daniele surname: Mercatelli fullname: Mercatelli, Daniele – sequence: 3 givenname: Letizia surname: Polito fullname: Polito, Letizia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31139079$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kc9vFCEcxYmpsbX27snM0YO7DjAwcDFp6q9Nqk2Mnsl34EuXZmYYYaZJ_3vZ3da0JnKB8H3v8yDvJTka44iEvKb1mnOl3_tpC2nNaqrXdd0o-YycUCn5SivKjh6dj8lZzjd1WVxrLpsX5JhTynXd6hNy9S0OMblgobIFB-Mc4F0F1fdlTmBxmcukr86nKUWw28rHVG1G38MwwBzTXfUDe5jRVR9DRsiYX5HnHvqMZ_f7Kfn1-dPPi6-ry6svm4vzy5VtJJtXzDFlodVeSNq5FrxiAigVLYC30jvrNFJvtWscbYSAjmlLQdCOoUflLD8lmwPXRbgxUwoDpDsTIZj9RUzXBlJ5fI-Gtcx5j8Bb5xrAtlOWKWp5x6SvfYuF9eHAmpZuQGdxLH_vn0CfTsawNdfx1khBW6lFAby9B6T4e8E8myFki30PI8YlG8Y4VUKohhfpm8dZf0MeGikCeRDYFHNO6I0NM8wh7qJDb2htdu2bfftm177Zt1-M9T_GB_Z_LX8As9y14A |
| CitedBy_id | crossref_primary_10_1080_13880209_2022_2077766 crossref_primary_10_1016_j_sajb_2022_10_006 crossref_primary_10_1155_2024_1987547 crossref_primary_10_1016_j_cpb_2025_100446 crossref_primary_10_1111_jfpe_14516 crossref_primary_10_3390_toxins13120862 crossref_primary_10_1080_07391102_2024_2439043 crossref_primary_10_3390_pharmaceutics14091796 crossref_primary_10_5010_JPB_2024_51_010_089 crossref_primary_10_2174_1573399819666230427095200 crossref_primary_10_1007_s11816_024_00953_x crossref_primary_10_1016_j_plaphy_2023_107663 crossref_primary_10_1094_PDIS_11_21_2500_PDN crossref_primary_10_3390_horticulturae10010041 crossref_primary_10_3390_bioengineering9090478 crossref_primary_10_1097_MD_0000000000026606 crossref_primary_10_3389_fphar_2020_00630 crossref_primary_10_3390_nu14173601 crossref_primary_10_3390_horticulturae10040309 crossref_primary_10_1007_s40995_023_01546_z crossref_primary_10_1016_j_plaphy_2024_108479 crossref_primary_10_33483_jfpau_1393243 crossref_primary_10_2174_1381612826666201222154159 crossref_primary_10_1080_10408398_2021_1900058 crossref_primary_10_1155_2021_6650704 crossref_primary_10_1016_j_phrs_2021_105693 crossref_primary_10_3390_ph16040523 crossref_primary_10_2174_1573399816666201103143225 crossref_primary_10_35118_apjmbb_2024_032_2_01 crossref_primary_10_1016_j_heliyon_2023_e21693 crossref_primary_10_3390_molecules26092682 crossref_primary_10_21605_cukurovaumfd_1459307 crossref_primary_10_3389_fnut_2023_1200801 crossref_primary_10_1080_07391102_2024_2313156 crossref_primary_10_1134_S1062359022602646 crossref_primary_10_1590_s0102_0536_20210408 crossref_primary_10_1007_s40203_021_00100_2 crossref_primary_10_1016_j_sajb_2024_05_030 crossref_primary_10_1021_acs_jafc_4c06506 crossref_primary_10_3390_horticulturae6040072 crossref_primary_10_1007_s00394_020_02338_6 crossref_primary_10_1016_j_nut_2020_110788 crossref_primary_10_1186_s40538_023_00433_4 crossref_primary_10_3390_toxins12090538 crossref_primary_10_46810_tdfd_1162900 crossref_primary_10_1007_s13365_023_01160_0 crossref_primary_10_3390_fermentation9060523 crossref_primary_10_1016_j_dcmed_2022_10_003 crossref_primary_10_1016_j_jff_2021_104720 crossref_primary_10_3390_toxins13020081 crossref_primary_10_3390_fermentation9080718 crossref_primary_10_3390_nano11092278 crossref_primary_10_14302_issn_2379_7835_ijn_23_4737 crossref_primary_10_3390_metabo11110763 crossref_primary_10_3390_ph12040152 crossref_primary_10_1186_s43014_022_00089_x crossref_primary_10_3390_cells12060825 crossref_primary_10_2478_fhort_2025_0001 crossref_primary_10_52711_0974_360X_2024_00215 crossref_primary_10_1016_j_jafr_2023_100680 crossref_primary_10_1080_15287394_2022_2157354 crossref_primary_10_1080_23311932_2023_2242634 crossref_primary_10_1002_jez_2854 crossref_primary_10_71336_jabs_1407 crossref_primary_10_1039_D2FO02096C crossref_primary_10_1016_j_foodchem_2020_128119 crossref_primary_10_3390_ijms23031071 crossref_primary_10_1186_s12985_023_02010_5 crossref_primary_10_1016_j_matpr_2021_04_006 crossref_primary_10_1016_j_phrs_2025_107626 crossref_primary_10_1186_s13048_021_00872_3 crossref_primary_10_1039_D1FO02788C crossref_primary_10_1155_2021_6671129 crossref_primary_10_2174_1381612826666200417160049 crossref_primary_10_3390_ijms251910518 crossref_primary_10_3390_molecules27113440 crossref_primary_10_1016_j_foodchem_2024_138479 crossref_primary_10_3390_ijms22073289 crossref_primary_10_1016_j_biopha_2022_113322 crossref_primary_10_3390_nu16213709 crossref_primary_10_55071_ticaretfbd_1356139 crossref_primary_10_3390_nano11030792 crossref_primary_10_1096_fj_202000502 crossref_primary_10_18231_j_ijcaap_2023_013 crossref_primary_10_22159_ijap_2024v16s5_52468 crossref_primary_10_3390_molecules27134278 crossref_primary_10_1007_s11306_023_01981_4 crossref_primary_10_3390_ani12111341 crossref_primary_10_2174_1871526522666220113143358 crossref_primary_10_3390_ijms24109085 crossref_primary_10_3390_plants11202722 crossref_primary_10_1038_s41598_022_19686_4 |
| Cites_doi | 10.1158/0008-5472.CAN-09-3438 10.1007/s12033-008-9034-y 10.1002/(sici)1097-0215(19960208)65:4<485::aid-ijc16>3.0.co;2-9 10.3390/toxins7051556 10.1155/2017/9478048 10.3390/molecules21121627 10.1016/j.ctcp.2018.06.012 10.3746/pnf.2013.18.1.018 10.1046/j.1365-2141.1998.00665.x 10.1016/j.ejphar.2012.05.033 10.4103/ijn.IJN_313_16 10.1017/S0007114515002093 10.1007/s10637-014-0156-8 10.1016/j.phytochem.2018.10.009 10.1016/j.plefa.2005.04.013 10.1155/2013/702869 10.1155/2016/5698931 10.1021/jf8020877 10.1016/S0378-8741(00)00213-0 10.1186/s12944-018-0896-0 10.1371/journal.pone.0159985 10.1016/j.biocel.2012.04.013 10.12860/jnp.2014.08 10.1016/j.jep.2016.10.043 10.1515/jvetres-2017-0063 10.1016/j.jep.2012.12.012 10.1002/ptr.6087 10.1016/j.indcrop.2016.10.046 10.1186/s41110-016-0013-y 10.1371/journal.pone.0084075 10.1155/2015/496169 10.1111/j.1349-7006.2010.01669.x 10.1016/j.ijms.2012.07.022 10.1016/j.foodchem.2009.05.058 10.1016/j.fct.2018.05.024 10.1007/s11418-011-0510-5 10.1158/1940-6207.CAPR-09-0088 10.1111/j.1750-3841.2008.00886.x 10.21037/atm.2018.12.08 10.1155/2017/3707046 10.1016/j.ijbiomac.2017.01.074 10.1155/2012/261971 10.1007/s13197-015-1886-0 10.1016/j.canlet.2012.05.005 10.1046/j.1365-2141.1995.404942.x 10.1016/j.neuropharm.2014.11.020 10.1155/2013/935675 10.1016/j.lwt.2009.03.006 10.1055/s-0034-1383307 10.1016/j.jff.2013.09.002 10.1007/s11095-010-0057-2 10.1021/jf800052y 10.1016/j.redox.2018.101070 10.1016/S1572-5995(05)80062-6 10.3390/biomedicines4020012 10.1142/S0192415X18500222 10.1016/j.jep.2018.10.033 10.1007/s13258-017-0642-4 10.3390/nu10101368 10.1093/ajhp/60.4.356 10.1016/S1875-5364(16)60002-X 10.3945/jn.113.187450 10.3390/molecules21040454 10.1046/j.1365-2362.2002.0320s1061.x 10.1186/1742-2094-8-64 10.7603/s40681-014-0017-y 10.1002/ijc.24325 10.1016/j.jchromb.2012.03.017 10.1016/j.canlet.2011.02.041 10.1016/j.fitote.2014.11.009 10.1016/j.jep.2009.01.028 10.1007/bf01741174 10.1142/S0192415X02000302 10.1016/j.jep.2004.03.035 10.1016/j.ijbiomac.2016.01.023 10.1002/jsfa.4251 10.1016/S0944-7113(96)80080-8 10.3390/molecules21111560 10.3390/molecules190812777 10.1186/s12906-017-1833-x 10.1155/2016/3527579 10.1039/c5fo00550g 10.1016/j.ijbiomac.2018.01.008 10.1016/j.coph.2017.05.007 10.1158/1940-6207.CAPR-11-0376 10.1007/s10495-011-0684-z 10.1016/j.phymed.2018.03.023 10.1002/ijc.20179 10.1016/j.phymed.2018.03.047 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 Bortolotti, Mercatelli and Polito. 2019 Bortolotti, Mercatelli and Polito |
| Copyright_xml | – notice: Copyright © 2019 Bortolotti, Mercatelli and Polito. 2019 Bortolotti, Mercatelli and Polito |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fphar.2019.00486 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals (WRLC) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1663-9812 |
| ExternalDocumentID | oai_doaj_org_article_272dffea37dd4ae7b8c281c3b26f0f7e PMC6517695 31139079 10_3389_fphar_2019_00486 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: Roberto and Cornelia Pallotti’s Legacy for Cancer Research |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM IAO IEA IHR IHW IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c462t-2d28ca79f561bd7af825a1157aafc6fdcd9e1fc9d4d1455ab29c1a51b2efe8dc3 |
| IEDL.DBID | M48 |
| ISSN | 1663-9812 |
| IngestDate | Wed Aug 27 01:27:04 EDT 2025 Thu Aug 21 18:32:27 EDT 2025 Thu Jul 10 17:24:36 EDT 2025 Thu Jan 02 23:01:42 EST 2025 Tue Jul 01 03:27:19 EDT 2025 Thu Apr 24 23:04:14 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | natural products bitter gourd nutraceuticals Momordica charantia bitter melon anti-inflammatory agents anti-cancer agents |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-2d28ca79f561bd7af825a1157aafc6fdcd9e1fc9d4d1455ab29c1a51b2efe8dc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 Reviewed by: Mohammed Rahmatullah, University of Development Alternative, Bangladesh; Elena Azzini, The Council for Agricultural Research and Economics, Italy; Jimmy Thomas Efird, University of Newcastle, Australia Edited by: Ilaria Peluso, Council for Agricultural and Economics Research, Italy This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fphar.2019.00486 |
| PMID | 31139079 |
| PQID | 2231855843 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_272dffea37dd4ae7b8c281c3b26f0f7e pubmedcentral_primary_oai_pubmedcentral_nih_gov_6517695 proquest_miscellaneous_2231855843 pubmed_primary_31139079 crossref_citationtrail_10_3389_fphar_2019_00486 crossref_primary_10_3389_fphar_2019_00486 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-05-08 |
| PublicationDateYYYYMMDD | 2019-05-08 |
| PublicationDate_xml | – month: 05 year: 2019 text: 2019-05-08 day: 08 |
| PublicationDecade | 2010 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in pharmacology |
| PublicationTitleAlternate | Front Pharmacol |
| PublicationYear | 2019 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Grossmann (B32) 2009; 2 Nerurkar (B60) 2010; 27 Gupta (B35) 2011; 11 Bao (B5) 2013; 8 Nagasawa (B59) 2002; 30 Alam (B1) 2015; 2015 Myojin (B58) 2008; 73 Saad (B76) 2017; 17 Yadav (B91) 2016; 53 Yasui (B93) 2005; 73 Fachinan (B22); 2017 Porro (B69) 1993; 36 Tan (B84) 2016; 85 Battelli (B8) 2016; 2016 Xu (B90) 2014; 144 Mardani (B55) 2014; 3 He (B37) 2018; 31 Peter (B64) 2019; 231 Kim (B43) 2018; 10 Kobori (B45); 56 Jones (B40) 2018; 42 Raman (B72) 1996; 2 Stepka (B81) 1974; 37 Zhang (B97) 2015; 33 Kobori (B44); 56 Minihane (B57) 2015; 114 Lii (B52) 2009; 122 Gosselaar (B31) 2002; 32 Hsu (B38) 2013; 5 Deng (B20) 2019; 7 Fachinan (B23); 2017 Ray (B73) 2010; 70 Lin (B53) 2012; 32 Nyam (B62) 2013; 42 Fan (B24) 2008; 39 Beniwal (B10) 2017; 27 Padmashree (B63) 2010; 91 Dandawate (B18) 2016; 14 Bolognesi (B13) 1998; 101 Polito (B68); 4 Weng (B88) 2013; 2013 Basch (B6) 2003; 60 Yue (B95) 2019; 157 Battelli (B7) 1996; 65 Raish (B71) 2018; 111 Marelli (B56) 2017; 35 Yoshime (B94) 2016; 41 Pitchakarn (B65) 2010; 101 Kwatra (B47) 2013; 2013 Chao (B15) 2014; 19 Polito (B67); 21 Bolognesi (B12) 2016; 21 Ciou (B17) 2014; 4 Bai (B3) 2016; 194 Kai (B41) 2011; 65 Fang (B25); 17 Liu (B54) 2010; 118 Ru (B75) 2011; 4 Yang (B92) 2018; 46 Nerurkar (B61) 2011; 8 Xiong (B89) 2009; 125 Fang (B26); 324 Raish (B70) 2017; 97 Biswas (B11) 2016; 2016 Terenzi (B85) 1996; 92 Li (B50); 89 Güdr (B34) 2016; 15 Kohno (B46) 2004; 110 Huang (B39) 2015; 8 Ghous (B29) 2015; 28 Liaw (B51) 2015; 81 Cheng (B16) 2012; 689 Schrot (B79) 2015; 7 Salehi (B77) 2018; 32 Soo May (B80) 2018; 32 Rios (B74) 2005 Scartezzini (B78) 2000; 71 Svobodova (B83) 2017; 98 Farooqi (B28) 2018; 119 Sung (B82) 2018; 42 Fang (B27); 44 Emre (B21) 2017; 61 Gong (B30) 2015; 91 Gürdal (B36) 2013; 146 Pitchakarn (B66) 2011; 306 Bai (B4) 2018; 40 Battelli (B9) 2018; 21 Kim (B42) 2013; 18 Li (B49); 2012 Grover (B33) 2004; 93 Cao (B14) 2015; 100 Aljohi (B2) 2016; 11 Deep (B19) 2004; 42 Tsai (B87) 2016; 21 Zeng (B96) 2018; 17 Lee-Huang (B48) 2000; 20 Tripathi (B86) 2010; 47 |
| References_xml | – volume: 70 start-page: 1925 year: 2010 ident: B73 article-title: Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-09-3438 – volume: 39 start-page: 79 year: 2008 ident: B24 article-title: Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells. publication-title: Mol. Biotechnol. doi: 10.1007/s12033-008-9034-y – volume: 65 start-page: 485 year: 1996 ident: B7 article-title: Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line. publication-title: Int. J. Cancer doi: 10.1002/(sici)1097-0215(19960208)65:4<485::aid-ijc16>3.0.co;2-9 – volume: 7 start-page: 1556 year: 2015 ident: B79 article-title: Ribosome-inactivating and related proteins. publication-title: Toxins doi: 10.3390/toxins7051556 – volume: 2017 ident: B22 article-title: Evidence of immunosuppressive and th2 immune polarizing effects of antidiabetic Momordica charantia fruit juice. publication-title: Biomed. Res. Int. doi: 10.1155/2017/9478048 – volume: 21 year: 2016 ident: B12 article-title: Ribosome-inactivating proteins from plants: a historical overview. publication-title: Molecules doi: 10.3390/molecules21121627 – volume: 32 start-page: 181 year: 2018 ident: B80 article-title: The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: a single-blinded, randomized controlled trial. publication-title: Complement. Ther. Clin. Pract. doi: 10.1016/j.ctcp.2018.06.012 – volume: 18 start-page: 18 year: 2013 ident: B42 article-title: The butanol fraction of bitter melon (Momordica charantia) scavenges free radicals and attenuates oxidative stress. publication-title: Prev. Nutr. Food Sci. doi: 10.3746/pnf.2013.18.1.018 – volume: 101 start-page: 179 year: 1998 ident: B13 article-title: Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. publication-title: Br. J. Haematol. doi: 10.1046/j.1365-2141.1998.00665.x – volume: 689 start-page: 241 year: 2012 ident: B16 article-title: EMCD, a hypoglycemic triterpene isolated from Momordica charantia wild variant, attenuates TNF-alpha-induced inflammation in FL83B cells in an AMP-activated protein kinase-independent manner. publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2012.05.033 – volume: 15 start-page: 301 year: 2016 ident: B34 article-title: Influence of total anthocyanins from bitter melon (Momordica charantia Linn.) as antidiabetic and radical scavenging agents. publication-title: Iran J. Pharm. Res. – volume: 27 start-page: 459 year: 2017 ident: B10 article-title: How harmful can herbal remedies be? A case of severe acute tubulointerstitial nephritis. publication-title: Indian J. Nephrol. doi: 10.4103/ijn.IJN_313_16 – volume: 114 start-page: 999 year: 2015 ident: B57 article-title: Low-grade inflammation, diet composition and health: current research evidence and its translation. publication-title: Br. J. Nutr. doi: 10.1017/S0007114515002093 – volume: 33 start-page: 1 year: 2015 ident: B97 article-title: Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma. publication-title: Invest. New Drugs doi: 10.1007/s10637-014-0156-8 – volume: 157 start-page: 21 year: 2019 ident: B95 article-title: Cucurbitane triterpenoids from the fruit of Momordica charantia L. and their anti-hepatic fibrosis and anti-hepatoma activities. publication-title: Phytochemistry doi: 10.1016/j.phytochem.2018.10.009 – volume: 73 start-page: 113 year: 2005 ident: B93 article-title: Bitter gourd seed fatty acid rich in 9c,11t,13t-conjugated linolenic acid induces apoptosis and up-regulates the GADD45, p53 and PPARgamma in human colon cancer Caco-2 cells. publication-title: Prostaglandins Leukot Essent Fatty Acids doi: 10.1016/j.plefa.2005.04.013 – volume: 2013 year: 2013 ident: B47 article-title: Methanolic extracts of bitter melon inhibit colon cancer stem cells by affecting energy homeostasis and autophagy. publication-title: Evid. Based Complement. Alternat. Med. doi: 10.1155/2013/702869 – volume: 2016 year: 2016 ident: B11 article-title: Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? publication-title: Oxid. Med. Cell Longev. doi: 10.1155/2016/5698931 – volume: 56 start-page: 10515 ident: B45 article-title: Alpha-eleostearic acid and its dihydroxy derivative are major apoptosis-inducing components of bitter gourd. publication-title: J. Agric. Food Chem. doi: 10.1021/jf8020877 – volume: 71 start-page: 23 year: 2000 ident: B78 article-title: Review on some plants of Indian traditional medicine with antioxidant activity. publication-title: J. Ethnopharmacol. doi: 10.1016/S0378-8741(00)00213-0 – volume: 31 start-page: 1837 year: 2018 ident: B37 article-title: Hypolipidemic and antioxidant potential of bitter gourd (Momordica charantia L.) leaf in mice fed on a high-fat diet. publication-title: Pak. J. Pharm. Sci. – volume: 17 year: 2018 ident: B96 article-title: Bitter melon (Momordica charantia) attenuates atherosclerosis in apo-E knock-out mice possibly through reducing triglyceride and anti-inflammation. publication-title: Lipids Health Dis. doi: 10.1186/s12944-018-0896-0 – volume: 11 year: 2016 ident: B2 article-title: Antiglycation and antioxidant properties of Momordica charantia. publication-title: PLoS One doi: 10.1371/journal.pone.0159985 – volume: 44 start-page: 1351 ident: B27 article-title: In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. publication-title: Int. J. Biochem. Cell Biol. doi: 10.1016/j.biocel.2012.04.013 – volume: 3 start-page: 35 year: 2014 ident: B55 article-title: Impact of Momordica charantia extract on kidney function and structure in mice. publication-title: J. Nephropathol. doi: 10.12860/jnp.2014.08 – volume: 194 start-page: 717 year: 2016 ident: B3 article-title: Response of gut microbiota and inflammatory status to bitter melon (Momordica charantia L.) in high fat diet induced obese rats. publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2016.10.043 – volume: 20 start-page: 653 year: 2000 ident: B48 article-title: Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. publication-title: Anticancer Res. – volume: 61 start-page: 489 year: 2017 ident: B21 article-title: Effect of intrauterine infusion of Momordica charantia L. on oxidative stress and pregnancy rate in infertile cows. publication-title: J. Vet. Res. doi: 10.1515/jvetres-2017-0063 – volume: 146 start-page: 113 year: 2013 ident: B36 article-title: An ethnobotanical study of medicinal plants in Marmaris (Muğla, Turkey). publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2012.12.012 – volume: 32 start-page: 1425 year: 2018 ident: B77 article-title: Phytotherapeutics in cancer invasion and metastasis. publication-title: Phytother. Res. doi: 10.1002/ptr.6087 – volume: 98 start-page: 365 year: 2017 ident: B83 article-title: Bioactive properties and phenolic profile of Momordica charantia L. medicinal plant growing wild in Trinidad and Tobago. publication-title: Ind. Crops Prod. doi: 10.1016/j.indcrop.2016.10.046 – volume: 41 year: 2016 ident: B94 article-title: Bitter gourd (Momordica charantia L.) seed oil as a naturally rich source of bioactive compounds for nutraceutical purposes. publication-title: Nutrire doi: 10.1186/s41110-016-0013-y – volume: 8 year: 2013 ident: B5 article-title: Momordica charantia, (bitter melon) reduces obesity-associated macrophage and mast cell infiltration as well as inflammatory cytokine expression in adipose tissues. publication-title: PLoS One doi: 10.1371/journal.pone.0084075 – volume: 2015 year: 2015 ident: B1 article-title: Beneficial role of bitter melon supplementation in obesity and related complications in metabolic syndrome. publication-title: J. Lipids doi: 10.1155/2015/496169 – volume: 101 start-page: 2234 year: 2010 ident: B65 article-title: Momordica charantia leaf extract suppresses rat prostate cancer progression in vitro and in vivo. publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2010.01669.x – volume: 32 start-page: 43 year: 2012 ident: B53 article-title: Structural characterization and identification of five triterpenoid saponins isolated from Momordica cochinchinensis extracts by liquid chromatography/tandem mass spectrometry. publication-title: Int. J. Mass Spectrom. doi: 10.1016/j.ijms.2012.07.022 – volume: 118 start-page: 751 year: 2010 ident: B54 article-title: Antioxidant triterpenoids from the stems of Momordica charantia. publication-title: Food Chem. doi: 10.1016/j.foodchem.2009.05.058 – volume: 119 start-page: 98 year: 2018 ident: B28 article-title: Bitter gourd (Momordica charantia) as a rich source of bioactive components to combat cancer naturally: are we on the right track to fully unlock its potential as inhibitor of deregulated signaling pathways. publication-title: Food Chem. Toxicol. doi: 10.1016/j.fct.2018.05.024 – volume: 65 start-page: 651 year: 2011 ident: B41 article-title: Inhibition of proliferation by agricultural plant extracts in seven human adult T-cell leukaemia (ATL)-related cell lines. publication-title: J. Nat. Med. doi: 10.1007/s11418-011-0510-5 – volume: 2 start-page: 879 year: 2009 ident: B32 article-title: Eleostearic acid inhibits breast cancer proliferation by means of an oxidation-dependent mechanism. publication-title: Cancer Prev. Res. doi: 10.1158/1940-6207.CAPR-09-0088 – volume: 73 start-page: C546 year: 2008 ident: B58 article-title: Changes in the radical-scavenging activity of bitter gourd (Momordica charantia L.) during freezing and frozen storage with or without blanching. publication-title: J. Food Sci. doi: 10.1111/j.1750-3841.2008.00886.x – volume: 7 year: 2019 ident: B20 article-title: Behavioral defects induced by chronic social defeat stress are protected by Momordica charantia polysaccharides via attenuation of JNK3/PI3K/AKT neuroinflammatory pathway. publication-title: Ann. Transl. Med. doi: 10.21037/atm.2018.12.08 – volume: 2017 ident: B23 article-title: Effectiveness of antihyperglycemic effect of Momordica charantia: implication of t-cell cytokines. publication-title: Evid. Based Complement. Alternat. Med. doi: 10.1155/2017/3707046 – volume: 97 start-page: 544 year: 2017 ident: B70 article-title: Momordica charantia polysaccharides ameliorate oxidative stress, hyperlipidemia, inflammation, and apoptosis during myocardial infarction by inhibiting the NF-κB signaling pathway. publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2017.01.074 – volume: 2012 ident: B49 article-title: Momordica charantia extract induces apoptosis in human cancer cells through caspase- and mitochondria-dependent pathways. publication-title: Evid. Based Complement. Alternat. Med. doi: 10.1155/2012/261971 – volume: 53 start-page: 1823 year: 2016 ident: B91 article-title: Antioxidant activity of various extracts of selected gourd vegetables. publication-title: J. Food Sci. Technol. doi: 10.1007/s13197-015-1886-0 – volume: 42 start-page: 319 year: 2004 ident: B19 article-title: Cancer preventive potential of Momordica charantia L. against benzo(a)pyrene induced fore-stomach tumourigenesis in murine model system. publication-title: Indian J. Exp. Biol. – volume: 324 start-page: 66 ident: B26 article-title: The MAP30 protein from bitter gourd (Momordica charantia) seeds vitro promotes apoptosis in liver cancer cells in vivo in. publication-title: Cancer Lett. doi: 10.1016/j.canlet.2012.05.005 – volume: 47 start-page: 227 year: 2010 ident: B86 article-title: Anti-hyperglycemic and anti-oxidative effect of aqueous extract of Momordica charantia pulp and Trigonella foenum graecum seed in alloxan-induced diabetic rats. publication-title: Indian J. Biochem. Biophys. – volume: 92 start-page: 872 year: 1996 ident: B85 article-title: Anti-CD30 (BER = H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. publication-title: Br. J. Haematol. doi: 10.1046/j.1365-2141.1995.404942.x – volume: 37 year: 1974 ident: B81 article-title: Antifertility investigation on Momordica. publication-title: Lloydia – volume: 91 start-page: 123 year: 2015 ident: B30 article-title: Momordica charantia polysaccharides could protect against cerebral ischemia/reperfusion injury through inhibiting oxidative stress mediated c-Jun N-terminal kinase 3 signaling pathway. publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2014.11.020 – volume: 2013 year: 2013 ident: B88 article-title: Cucurbitane triterpenoid from Momordica charantia induces apoptosis and autophagy in breast cancer cells, in part, through peroxisome proliferator-activated receptor γ activation. publication-title: Evid. Based Complement. Alternat. Med. doi: 10.1155/2013/935675 – volume: 42 start-page: 1396 year: 2013 ident: B62 article-title: Physicochemical properties and bioactive compounds of selected seed oils. publication-title: LWT-Food Sci. Technol. doi: 10.1016/j.lwt.2009.03.006 – volume: 11 start-page: 32 year: 2011 ident: B35 article-title: Momordica charantia Linn, (karela): nature’s silent healer. publication-title: Int. J. Pharm. Sci. Rev. Res. – volume: 81 start-page: 62 year: 2015 ident: B51 article-title: 5β,19-epoxycucurbitane triterpenoids from Momordica charantia and their anti-inflammatory and cytotoxic activity. publication-title: Planta Med. doi: 10.1055/s-0034-1383307 – volume: 5 start-page: 1829 year: 2013 ident: B38 article-title: Inhibitory effects of new varieties of bitter melon on lipopolysaccharide-stimulated inflammatory response in RAW 264.7 cells. publication-title: J. Funct. Foods doi: 10.1016/j.jff.2013.09.002 – volume: 27 start-page: 1049 year: 2010 ident: B60 article-title: Bitter melon: antagonist to cancer. publication-title: Pharm. Res. doi: 10.1007/s11095-010-0057-2 – volume: 56 start-page: 4004 ident: B44 article-title: Bitter gourd suppresses lipopolysaccharide-induced inflammatory responses. publication-title: J. Agric. Food Chem. doi: 10.1021/jf800052y – volume: 21 year: 2018 ident: B9 article-title: Metabolic syndrome and cancer risk: the role of xanthine oxidoreductase. publication-title: Redox Biol. doi: 10.1016/j.redox.2018.101070 – start-page: 429 year: 2005 ident: B74 publication-title: Studies in Natural Products Chemistry doi: 10.1016/S1572-5995(05)80062-6 – volume: 4 ident: B68 article-title: Plant toxin-based immunotoxins for cancer therapy: a short overview. publication-title: Biomedicines doi: 10.3390/biomedicines4020012 – volume: 46 start-page: 435 year: 2018 ident: B92 article-title: Momordica charantia inhibits inflammatory responses in murine macrophages via suppression of TAK1. publication-title: Am. J. Chin. Med. doi: 10.1142/S0192415X18500222 – volume: 231 start-page: 311 year: 2019 ident: B64 article-title: Momordica charantia L. lowers elevated glycaemia in type 2 diabetes mellitus patients: aystematic review and meta-analysis. publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2018.10.033 – volume: 40 start-page: 561 year: 2018 ident: B4 article-title: Obese rats supplemented with bitter melon display marked shifts in the expression of genes controlling inflammatory response and lipid metabolism by RNA-Seq analysis of colonic mucosa. publication-title: Genes Genomics doi: 10.1007/s13258-017-0642-4 – volume: 10 year: 2018 ident: B43 article-title: Momordica charantia ethanol extract attenuates H2O2-induced cell death by its antioxidant and anti-apoptotic properties in human neuroblastoma SK-N-MC cells. publication-title: Nutrients doi: 10.3390/nu10101368 – volume: 60 start-page: 356 year: 2003 ident: B6 article-title: Bitter melon (Momordica charantia): a review of efficacy and safety. publication-title: Am. J. Health Syst. Pharm. doi: 10.1093/ajhp/60.4.356 – volume: 14 start-page: 81 year: 2016 ident: B18 article-title: Bitter melon: a panacea for inflammation and cancer. publication-title: Chin. J. Nat. Med. doi: 10.1016/S1875-5364(16)60002-X – volume: 144 start-page: 475 year: 2014 ident: B90 article-title: Bitter gourd inhibits the development of obesity-associated fatty liver in C57BL/6 mice fed a high-fat diet. publication-title: J. Nutr. doi: 10.3945/jn.113.187450 – volume: 21 year: 2016 ident: B87 article-title: Wild bitter melon leaf extract inhibits Porphyromonas gingivalis-induced inflammation: identification of active compounds through bioassay-guided isolation. publication-title: Molecules doi: 10.3390/molecules21040454 – volume: 32 start-page: 61 year: 2002 ident: B31 article-title: Transferrin toxin but not transferrin receptor immunotoxin is influenced by free transferrin and iron saturation. publication-title: Eur. J. Clin. Invest. doi: 10.1046/j.1365-2362.2002.0320s1061.x – volume: 8 start-page: 1 year: 2011 ident: B61 article-title: Momordica charantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. publication-title: J. Neuroinflamm. doi: 10.1186/1742-2094-8-64 – volume: 4 year: 2014 ident: B17 article-title: Effect of wild bitter gourd treatment on inflammatory responses in BALB/c mice with sepsis. publication-title: Biomedicine (Taipei) doi: 10.7603/s40681-014-0017-y – volume: 125 start-page: 774 year: 2009 ident: B89 article-title: Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells. publication-title: Int. J. Cancer doi: 10.1002/ijc.24325 – volume: 89 start-page: 77 ident: B50 article-title: Application of high-speed counter-current chromatography coupled with a reverse micelle solvent system to separate three proteins from Momordica charantia. publication-title: J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. doi: 10.1016/j.jchromb.2012.03.017 – volume: 306 start-page: 142 year: 2011 ident: B66 article-title: Induction of G1 arrest and apoptosis in androgen-dependent human prostate cancer by Kuguacin J, a triterpenoid from Momordica charantia leaf. publication-title: Cancer Lett. doi: 10.1016/j.canlet.2011.02.041 – volume: 28 start-page: 1217 year: 2015 ident: B29 article-title: Comparative study of antioxidant, metal chelating and antiglycation activities of Momordica charantia flesh and pulp fractions. publication-title: Pak. J. Pharm. Sci. – volume: 100 start-page: 139 year: 2015 ident: B14 article-title: Alpha-momorcharin (α-MMC) exerts effective anti-human breast tumor activities but has a narrow therapeutic window in vivo. publication-title: Fitoterapia doi: 10.1016/j.fitote.2014.11.009 – volume: 122 start-page: 227 year: 2009 ident: B52 article-title: Suppressive effects of wild bitter gourd (Momordica charantia Linn. var. abbreviata ser.) fruit extracts on inflammatory responses in RAW264.7 macrophages. publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2009.01.028 – volume: 36 start-page: 346 year: 1993 ident: B69 article-title: In vitro and in vivo properties of an anti-CD5-momordin immunotoxin on normal and neoplastic T lymphocytes. publication-title: Cancer Immunol. Immunother. doi: 10.1007/bf01741174 – volume: 30 start-page: 195 year: 2002 ident: B59 article-title: Effects of bitter melon (Momordica charantia L.) or ginger rhizome (Zingiber officinale Rosc) on spontaneous mammary tumorigenesis in SHN mice. publication-title: Am. J. Chin. Med. doi: 10.1142/S0192415X02000302 – volume: 93 start-page: 123 year: 2004 ident: B33 article-title: Pharmacological actions and potential uses of Momordica charantia: a review. publication-title: J. Ethnopharmacol. doi: 10.1016/j.jep.2004.03.035 – volume: 85 start-page: 487 year: 2016 ident: B84 article-title: Polysaccharide with antioxidant, α-amylase inhibitory and ACE inhibitory activities from Momordica charantia. publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2016.01.023 – volume: 91 start-page: 776 year: 2010 ident: B63 article-title: Studies on antioxygenic activity of bitter gourd (Momordica charantia) and its fractions using various in vitro models. publication-title: J. Sci. Food Agric. doi: 10.1002/jsfa.4251 – volume: 2 start-page: 349 year: 1996 ident: B72 article-title: Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). publication-title: Phytomedicine doi: 10.1016/S0944-7113(96)80080-8 – volume: 21 ident: B67 article-title: Plants producing ribosome-inactivating proteins in traditional medicine. publication-title: Molecules doi: 10.3390/molecules21111560 – volume: 19 start-page: 12777 year: 2014 ident: B15 article-title: Anti-inflammatory effect of Momordica charantia in sepsis mice. publication-title: Molecules doi: 10.3390/molecules190812777 – volume: 17 year: 2017 ident: B76 article-title: Effects of Karela (Bitter Melon; Momordica charantia) on genes of lipids and carbohydrates metabolism in experimental hypercholesterolemia: biochemical, molecular and histopathological study. publication-title: BMC Complement. Altern. Med. doi: 10.1186/s12906-017-1833-x – volume: 2016 year: 2016 ident: B8 article-title: Xanthine oxidoreductase-derived reactive species: physiological and pathological effects. publication-title: Oxid. Med. Cell Longev. doi: 10.1155/2016/3527579 – volume: 8 start-page: 2550 year: 2015 ident: B39 article-title: Inhibitory effects of wild bitter melon leaf extract on Propionibacterium acnes-induced skin inflammation in mice and cytokine production in vitro. publication-title: Food Funct. doi: 10.1039/c5fo00550g – volume: 111 start-page: 193 year: 2018 ident: B71 article-title: Momordica charantia polysaccharides ameliorate oxidative stress, inflammation, and apoptosis in ethanol-induced gastritis in mucosa through NF-kB signaling pathway inhibition. publication-title: Int. J. Biol. Macromol. doi: 10.1016/j.ijbiomac.2018.01.008 – volume: 35 start-page: 57 year: 2017 ident: B56 article-title: Inflammation as target in cancer therapy. publication-title: Curr. Opin. Pharmacol. doi: 10.1016/j.coph.2017.05.007 – volume: 4 start-page: 2122 year: 2011 ident: B75 article-title: Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model. publication-title: Cancer Prev. Res. doi: 10.1158/1940-6207.CAPR-11-0376 – volume: 17 start-page: 377 ident: B25 article-title: RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. publication-title: Apoptosis doi: 10.1007/s10495-011-0684-z – volume: 42 start-page: 90 year: 2018 ident: B82 article-title: The effects of wild bitter gourd fruit extracts on ICAM-1 expression in pulmonary epithelial cells of C57BL/6J mice and microRNA-221/222 knockout mice: involvement of the miR-221/-222/PI3K/AKT/NF-κB pathway. publication-title: Phytomedicine doi: 10.1016/j.phymed.2018.03.023 – volume: 110 start-page: 896 year: 2004 ident: B46 article-title: Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPARgamma expression and alteration of lipid composition. publication-title: Int. J. Cancer doi: 10.1002/ijc.20179 – volume: 42 start-page: 226 year: 2018 ident: B40 article-title: BG-4, a novel bioactive peptide from Momordica charantia, inhibits lipopolysaccharide-induced inflammation in THP-1 human macrophages. publication-title: Phytomedicine doi: 10.1016/j.phymed.2018.03.047 |
| SSID | ssj0000399364 |
| Score | 2.5058608 |
| SecondaryResourceType | review_article |
| Snippet | , commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and nutritional... Momordica charantia, commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and... Momordica charantia , commonly called bitter melon, is a plant belonging to Cucurbitaceae family known for centuries for its pharmacological activities, and... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 486 |
| SubjectTerms | anti-inflammatory agents bitter gourd bitter melon Momordica charantia natural products nutraceuticals Pharmacology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp15K33XTFhVKoLBmVw9L1jF9hLTQNIcEchNjSUMCjTd0dw_59x3J3s1uKe2lV1tGQt9I841n9Imxd2Q0rnHQ1qbTttaoZQ0zlHVAk7C10MpYqnxPzPG5_nrRXGxd9ZVrwgZ54GHiptLKiJhA2Rg1JNu1QbYiqE4anKFNefcln7cVTJU9OPtdo4e8JEVhboo3l5D1P0XWp9T56PSWHypy_X_imL-XSm75nqOH7MFIGvnhMNhH7F7qH7OD00F1-nbCz-4OUS0m_ICf3ulR3z5h37_NrynEJDR4PmNFU3kFEw78ZEV9rf9m88NRXJwTi-VfeiRLuS4ZeF7q5VLkn4ZczuIpOz_6fPbxuB7vUaiDNnJZyyjbANYhcaUuWkCKCiGL7ABgMBhDdElgcFHHLFsOnXRBQCM6mTC1MahnbK-f9-kF40IEMEE0YBxhi6oLUXdKKTQKolamYtP1rPowioznuy5-eAo2Mg6-4OAzDr7gULH3my9uBoGNv7T9kIHatMvS2OUBGYwfDcb_y2Aq9nYNs6ellPMj0Kf5auGJKRF7IUamKvZ8gH3TlRJElWfWVczuGMTOWHbf9FeXRa7bNMIa17z8H4PfZ_fzdJSKy_YV21v-XKXXxIqW3ZuyAH4B7JYQfQ priority: 102 providerName: Directory of Open Access Journals |
| Title | Momordica charantia, a Nutraceutical Approach for Inflammatory Related Diseases |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31139079 https://www.proquest.com/docview/2231855843 https://pubmed.ncbi.nlm.nih.gov/PMC6517695 https://doaj.org/article/272dffea37dd4ae7b8c281c3b26f0f7e |
| Volume | 10 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zb9QwELagvPCCuAlHZSRUCWlD10d8PCBUjqogtfShK_Utmvigldps2UNi_z1jJ7vLohXiNZcTfzOZbzz2Z0LeoNHYyoIpVSN1KaPkJQwjL11UIRoNhvs8y_dEHY3kt_PqfL08uu_A6dbULu0nNZpcvfv1c_EBHf59yjgx3u7HmwtI0p4sSU9Ko26TOxiXdHLT457s5_9yisVZT4phmC0thraubrn1IRtxKsv5b-Ogf0-l_CM2Hd4n93pSSQ86K3hAboX2Idk77VSpFwN6tl5kNR3QPXq61qtePCLfj8fXmIIiWjStwcKuvoQBBXoyx7aWo930oBcfp8hy6dc2oiVd5wo9zfPpgqefu1rP9DEZHX45-3RU9vsslE4qPiu558aBthG5VOM1RMwaIYnwAESnonfeBhad9dInWXNouHUMKtbwEIPxTjwhO-24Dc8IZcyBcqwCZRH7KBrnZSOEiEqAl0IVZH_Zq7XrRcjTXhhXNSYjCYc641AnHOqMQ0Heru646QQ4_nHtxwTU6roknZ0PjCc_6t4Ta665jzGA0N5LCLoxjhvmRMNVHEYdCvJ6CXONrpbqJ9CG8XxaI5NCdoOMTRTkaQf7qinBkEoPtS2I3jCIjXfZPNNeXmQ5b1UxrWz1_D_afUHupq_NEy7NS7Izm8zDKyRFs2Y3DybsZov_DVohDuM |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Momordica+charantia%2C+a+Nutraceutical+Approach+for+Inflammatory+Related+Diseases&rft.jtitle=Frontiers+in+pharmacology&rft.au=Bortolotti%2C+Massimo&rft.au=Mercatelli%2C+Daniele&rft.au=Polito%2C+Letizia&rft.date=2019-05-08&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=10&rft.spage=486&rft_id=info:doi/10.3389%2Ffphar.2019.00486&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon |